Evidence map›Paper›PMID 39809936›Full record

ArticleClinical and experimental nephrology2025

Chronic kidney disease is a major risk factor for mortality in triglyceride deposit cardiomyovasculopathy patients.

Yasuyuki Nagasawa, Satomi Okamura, Yuki Nishimura, Tomomi Yamada, Hideyuki Miyauchi, Yusuke Nakano, Tetsuya Amano, Yuko Kawaguchi, Shinichiro Fujimoto, Ken-Ichi Hirano and 1 more

Abstract read
In one paragraph

Article in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yasuyuki NagasawaDepartment of Internal Medicine, Hyogo Medical University, Nishinomiya, 663-8501, Japan. nagasawa@hyo-med.ac.jp.
Satomi OkamuraDepartment of Medical Innovation, Osaka University Hospital, Suita, 565-0871, Japan.
Yuki NishimuraDepartment of Medical Innovation, Osaka University Hospital, Suita, 565-0871, Japan.
Tomomi YamadaDepartment of Medical Innovation, Osaka University Hospital, Suita, 565-0871, Japan.
Hideyuki MiyauchiDepartment of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, 260-8670, Japan.
Yusuke NakanoDepartment of Cardiology, Aichi Medical University, Nagakute, 480-1195, Japan.
Tetsuya AmanoDepartment of Cardiology, Aichi Medical University, Nagakute, 480-1195, Japan.
Yuko KawaguchiDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, 113-8421, Japan.
Shinichiro FujimotoDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, 113-8421, Japan.
Ken-Ichi HiranoDepartment of Triglyceride Science, Graduate School of Medicine, Osaka University, Suita, 565-0874, Japan.
Japan TGCV study group

Funding

Japan Society for the Promotion of Science 23K09146
6 · The paper itself

Abstract

Triglyceride deposit cardiomyovasculopathy (TGCV) is a rare cardiovascular disorder caused by defective intracellular lipolysis of triglyceride, resulting in heart failure and diffuse narrowing atherosclerosis. Recently, the registry of TGCV patients in Japan revealed that the 3-year overall survival rate was 80.1% and the 5-year overall survival rate was 71.8%. In this study, the effect on mortality of chronic kidney disease (CKD), diabetes malleus (DM), hypertension (HT), and dyslipidemia (DL) was analyzed using this retrospective registry of TGCV patients. The 3-year survival rate was 71.3% in the CKD group and 91.7% in the non-CKD group, and the 5-year survival rate was 61.8% in CKD group and 84.4% in the non-CKD group. The Kaplan-Meier analysis revealed that CKD is a risk factor for mortality in TGCV patients (p = 0.006). Although TGCV patients with CKD were older than those without CKD, Cox proportional hazard model analyses including age indicated that CKD has a significant association of the prognosis of TGCV patients (hazard ratio 2.33 [1.12-4.86], p = 0.024). DM, HT, and DL did not increase mortality in TGCV patients, although these risk factors were established in the general population. TGCV might cause cardiac disorders and kidney disease at the same time, because podocyte foot process disorder in the glomeruli might be caused by TGCV itself, while CKD should be a risk factor for mortality in TGCV patients as is true in the general population. In conclusion, CKD is a major risk factor for mortality in TGCV patients and thus should be paid attention to in these patients.

Indexed as

CardiomyopathiesRenal Insufficiency, ChronicTriglyceridesAdultAgedDyslipidemiasFemaleHumansHypertensionJapanKaplan-Meier EstimateMaleMiddle AgedPrognosisProportional Hazards ModelsRegistriesTriglyceridesChronic kidney disease (CKD)MortalityTriglycerideTriglyceride deposit cardiomyovasculopathy

Identifiers

PMID39809936
PMCPMC12125078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.